I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Ischemic stroke is a major cause of death and disability worldwide, and the clinical prognosis of acute cerebral ischemia remains poor.\[[@ref1][@ref2]\] The brain is more sensitive to ischemia, compared to other organs, and neurons in the ischemic core thereby die within minutes, causing irreversible infarction. At present, it has been considered that the immediate restoration of blood supply in the cerebral and ischemic penumbra and saving dying neurons is the key to the treatment of cerebral infarction. Han\'s study\[[@ref3]\] revealed that in recovering the blood supply of ischemic tissues and saving dying neurons after the reperfusion of cerebral blood flow, the body produces a rapid cascade of damage on nerve cells through the combined effect of the complex link, and this eventually leads to neuronal apoptosis or necrosis, and ischemia-reperfusion injury (IRI), which induces further damage. Previous studies have confirmed that energy metabolism disorder, excitatory amino acid toxicity, brain edema, inflammatory cell infiltration, micro-angiogenesis factors, and apoptosis are involved in cerebral IRI.\[[@ref4][@ref5][@ref6][@ref7]\] Therefore, to reduce the IRI in nerve cell damage effectively and protect nerve cells, there is a need to find a good treatment approach. Since the present exogenous treatment measures for IRI is not ideal, endogenous treatment measures thus become a research focus at present.

Remote ischemic postconditioning (RIPostC) is the application of a transient and brief ischemic stimulus to a distant site from the organ or texture that is afterward exposed to injury ischemia\[[@ref8]\] and has been found to reduce IRI in various animal models. The idea of RIPostC initially stemmed from the protection against cardiac IRI by Murry *et al*.\[[@ref9]\] The RIPostC organ-protective effects on the animal experiment research mainly concentrated in important organs such as the heart, brain, liver, or spinal cord;\[[@ref10][@ref11][@ref12][@ref13]\] most researches have confirmed that RIPostC has clear organ-protective effects, and that the protective effect of RIPostC is correlated to stimulus parameters (such as ischemia time and time), which induces the body to achieve a threshold to produce protective information. Few animal studies on the protective effect of RIPostC on other organs, such as the lung, stomach, kidneys, and skin, have been conducted. In humans, RIPostC of the limb has been shown to be effective in protecting against global and focal cerebral ischemia.\[[@ref14][@ref15][@ref16]\] At present, the concept of RIPostC has been extended to different organs and tissues, and clinical trials have mainly focused on cardiac surgery, such as coronary artery bypass grafting and stent implantation. However, the results of several meta-analyses that evaluated the effect of RIPostC on cardiac and renal IRI injury prevention remained inconclusive.\[[@ref17][@ref18][@ref19][@ref20]\] To date, several clinical trials have been published which analyzed the role of RIPostC in the effect of ischemic stroke.\[[@ref21]\] However, published literatures are still limited and drawing conclusions from them remains controversial. Therefore, together with published randomized controlled trials (RCTs), a systematic review to evaluate the effect of RIPostC on brain protection in patients with stroke is needed.

The aim of the present study was to systematically assess the benefits of RIPostC versus no RIPostC in patients undergoing stroke.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Eligibility criteria {#sec2-1}
--------------------

**Participants**

Participants of any age, gender, or ethnic background, who suffered from stroke, were included in the RCTs.

**Interventions and controls**

In the RIPostC group, patients received RIPostC therapy, irrespective of the duration, time, and the limb. The control group included placebo, sham operation, or no treatment. When another treatment was combined with RIPostC, the adjunct treatment needed to be the same as the control.

**Outcomes measurement**

The primary outcome measure included the incidence rate of stroke or transient ischemic attack (TIA) recurrence and the National Institutes of Health Stroke Scale (NIHSS). Stroke and TIA were confirmed by magnetic resonance imaging/magnetic resonance angiography/diffusion-weighted imaging in combination with clinical manifestations. NIHSS was used to evaluate the degree of neurological deficits in patients with stroke, and baseline assessment determined the severity of stroke. The effect of treatment was assessed on a regular basis with reference to the awareness, eye movement, visual field, limb muscle strength and sensation, limb ataxia, language function, and cognitive performance and attention of the patients, as well as other aspects of the test. This was used to objectively reflect the degree of neurological impairment, and the score range applied was 0--42 points. The higher the score was, the more serious the nerve damage. Secondary outcomes included the modified Rankin Scale (mRS), high-sensitivity C-reactive protein (hs-CRP), plasma fibrinogen (FIB), and D dimer (D-D) level changes from the baseline.

**Study design**

The included published RCTs had no language restrictions.

**Exclusion criteria**

Studies that met the following criteria were excluded: (1) studies with participants who had any soft tissue or vascular injury and (2) studies that did not report any of the outcomes stated above.

Information sources {#sec2-2}
-------------------

**Electronic searches**

Two English databases (Cochrane Library and PubMed) and four Chinese databases (CNKI, VIP, Wanfang, and CBM) were comprehensively searched up to July 1, 2016. The searched words were divided into three categories: (1) condition (stroke); (2) intervention (remote ischemic preconditioning and RIPostC), remote ischemic preconditioning means intervention before issues of the attack, while RIPostC means intervention after the attack; (3) study type (RCTs). These search terms were adjusted for each database. The search strategy in PubMed is shown in [Supplementary Table 1](#T1){ref-type="table"}.

###### 

Search strategy in PubMed

  Categories                                          Search terms
  --------------------------------------------------- -----------------------------------------------------
  Condition                                           1\. Stroke (MeSH terms)
  2\. Strokes                                         
  3\. Apoplexy                                        
  4\. CVA                                             
  5\. CVAs                                            
  6\. Cerebrovascular accident                        
  7\. Cerebrovascular accidents                       
  8\. Cerebrovascular apoplexy                        
  9\. Apoplexy, cerebrovascular                       
  10\. Cerebrovascular stroke                         
  11\. Cerebrovascular strokes                        
  12\. Stroke, cerebrovascular                        
  13\. Strokes, cerebrovascular                       
  14\. Vascular accident, brain                       
  15\. Brain vascular accident                        
  16\. Brain vascular accidents                       
  17\. Vascular accidents, brain                      
  18\. Cerebral stroke                                
  19\. Cerebral strokes                               
  20\. Stroke, cerebral                               
  21\. Stroke, acute                                  
  22\. Acute stroke                                   
  23\. Acute strokes                                  
  24\. Strokes, acute                                 
  25\. Cerebrovascular accident, acute                
  26\. Acute cerebrovascular accident                 
  27\. Acute cerebrovascular accidents                
  28\. Cerebrovascular accidents, acute               
  29\. Brain infarction                               
  30\. Cerebral infarction                            
  31\. \#1-\#30/OR                                    
  Intervention                                        32\. RIPostC
  33\. Remote ischemic preconditioning                
  34\. Ischemic preconditioning                       
  35\. Ischemic preconditioning limb                  
  36\. Remote preconditioning                         
  37\. Remote ischemic postconditioning               
  38\. Ischemic postconditioning                      
  39\. Remote postconditioning                        
  40\. \#32-\#39/OR                                   
  Study type                                          41\. Randomized controlled trial (publication type)
  42\. Controlled clinical trial (publication type)   
  43\. Randomized (title/abstract)                    
  44\. Placebo (title/abstract)                       
  45\. Clinical trials as topic (MeSH: No extended)   
  46\. Randomly (title/abstract)                      
  47\. Trial (title)                                  
  48\. Animals (MeSH terms)                           
  49\. \#41-\#47/OR NOT (\#48 NOT \#49)               
  50\. \#31 AND \#40 AND \#49                         

Comprehensive Chinese search strategy: \#1: 中风 OR 脑梗死 OR 脑缺 血 OR 脑血管病; \#2: 远端缺血预处理 OR 远程缺血预处理 OR 远端 缺血预适应 OR 远程缺血预适应 OR 肢体缺血预适应 OR 肢体缺血 预处理 OR 远端缺血后适应 OR 远程缺血后处理 OR 远端缺血后适 应 OR 远程缺血后适应 OR 肢体缺血后适应 OR 肢体缺血后处理 \#3: \#1 AND \#2. (\#1: stroke OR cerebral infarction OR cerebral ischemia OR cerebrovascular disease; \#2: Remote ischemic preconditioning OR Ischemic preconditioning limb OR Remote ischemic postconditioning OR Ischemic postconditioning limb; \#3: \#1 AND \#2.) CVA: Cardiovascular accident; RIPostC: Remote ischemic postconditioning

**Searching for other sources**

References of recently reviewed articles and included studies were searched for additional studies.

Data collection {#sec2-3}
---------------

**Study selection**

The titles and abstracts of articles obtained from the database were independently analyzed by two investigators to ascertain the conformity of inclusion criteria. The full text of the articles was carefully reviewed when the screening of the titles and abstracts was unclear with regard to its admissibility.

**Data extraction process**

Two reviewers extracted the data after assessing and reaching consensus for eligible studies using a standardized data extraction form. Any conflicts between the two investigators (reviewers) were resolved by discussion with an arbitrator. The same reviewers independently assessed each trial and extracted data on the primary author, date of publication, journal, demographic characteristics of patients (age, gender, and sample size), protocol for RIPostC (location, timing and frequency), course of treatment, and outcomes (incidence of cerebrovascular event, NIHSS, mRS, etc.). Dichotomous data were collected as number (percentage), continuous data were collected as mean ± standard deviation, and the other forms were collected as stated in the articles.

Risk of bias assessment in the individual study {#sec2-4}
-----------------------------------------------

The included studies were evaluated for methodological quality using the Cochrane Collaboration\'s tool for assessing for risk of bias.\[[@ref22]\] Seven domains were evaluated, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Risk of other bias was judged by assessing the baseline balance, data management, funding source, and so on. Judgments were categorized as "low risk of bias," "high risk of bias," or "unclear."

Statistical analysis {#sec2-5}
--------------------

Statistical analyses were performed using Review Manager 5.2 (the Cochrane Collaboration, Copenhagen, Denmark). Risk ratios (*RR*s), with 95% confidence intervals (*CI*s), were calculated for dichotomous outcomes. The pooled effects of RIPostC on continuous outcomes were estimated using mean differences (MDs) with 95% *CI*. The meta-analyses were performed using Mantel-Haenszel fixed-effects models when there was no significant statistical heterogeneity in the included studies. A 5% level was taken as significant throughout the study.

**Synthesis of results**

Statistical heterogeneity was evaluated using the *I*^2^ statistic (*I*^2^ ≥50% was considered to indicate heterogeneity). The random-effects model was adopted when *I*^2^ was ≥50% without clinical heterogeneity.

**Additional analyses**

Subgroup analyses were predefined and performed for primary outcome measures and were used to assess the influence of variables on RIPostC efficacy, as well as to explore the possible causes of heterogeneity. Clinical heterogeneity between trials for the primary outcome was addressed by further subgroup analysis. The following important factors were noted: trials with low risk of bias versus those with high risk of bias; male versus female; treatment duration (≤14 days and \>14 days); RIPostC protocol (total duration/day \<90 min and ≥90 min); and stroke history (≤14 days and \>14 days). Chi-square test was performed, which was set at a *P* = 0.05, in order to identify any subgroup differences. The robustness of the analyses was assessed by performing sensitivity analyses, excluding studies from the overall analysis of high risk of bias, and by considering separate studies of different durations. In addition, studies that did not provide complete data and did not clearly report the dropout data were excluded.

Publication bias assessment {#sec2-6}
---------------------------

Publication bias was assessed when the group included more than 10 studies through the use of a funnel plot.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Study selection {#sec2-7}
---------------

The searching strategy generated 1436 articles. A total of 1411 articles were removed due to the following: duplicates, articles not related to RIPostC, articles not related to stroke, articles that are not clinical studies, or are other studies. Among these, 16 articles were excluded because these were either nonrandomized studies or evaluated interventions, or had outcomes that were not relevant to this review. The full-text assessment of 25 potentially relevant articles identified 13 eligible trials \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35]\]

![Flowchart of the study screening. RIPostC: Remote ischemic postconditioning; RCT: Randomized controlled trial.](CMJ-131-956-g001){#F1}

Study characteristics {#sec2-8}
---------------------

A total of 1251 participants were enrolled in the 13 studies, and all these studies involved TIA or cerebral infarction.\[[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35]\] The number of participants included in the trials ranged from 16\[[@ref35]\] to 286.\[[@ref27]\] The RIPostC method varied among studies: 12 studies used an inflatable tourniquet around the upper limb,\[[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref32][@ref33][@ref34][@ref35]\] while one study used pressure bandages around the lower limb.\[[@ref31]\] All the reported outcomes were measured at the end of treatment, but the timing of measurements varied across trials. The key characteristics of the included studies are summarized in Tables [1](#T2){ref-type="table"} and [2](#T3){ref-type="table"}.

###### 

Summarized study design of included randomized trials

  Study                          RIPostC protocol     Control             Course of treatment (days)   Outcomes reported   Side effect                                                                                                                                                                                                             
  ------------------------------ -------------------- ------------------- ---------------------------- ------------------- ------------- ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  Ma *et al*.\[[@ref35]\]        5 × 5 min × 5 min    200                 Upper arm                    90                  Blank         1800   Incidence of cerebrovascular accidents; mRS score and severity of stenotic cerebral vessel; serum cAMP; HIF-1; VEGF                                                                                NR
  Meng *et al*.\[[@ref34]\]      5 × 5 min × 5 min    200                 Upper arm                    90                  Placebo       300    Incidence of recurrent stroke; the time to which mRS recovers to 0--1; the time point of RIPostC intolerance                                                                                       NR
  Ru Juan *et al*.\[[@ref33]\]   5 × 5 min × 5 min    180--200            Upper arm                    45                  Blank         180    Incidence of recurrent stroke; cerebral metabolism and cerebral blood flow                                                                                                                         NR
  Wang *et al*.\[[@ref25]\]      3 × 5 min × 5 min    200                 Upper arm                    25                  Placebo       14     NIHSS score; BDNF                                                                                                                                                                                  NR
  Yang *et al*.\[[@ref32]\]      5 × 5 min × 5 min    180                 Upper arm                    90                  NR            180    Incidence of recurrent stroke                                                                                                                                                                      NR
  Peng *et al*.\[[@ref31]\]      3 × 5 min × 10 min   Pressure bandages   Thigh                        35                  Blank         14     NIHSS; BI scores and the FMA                                                                                                                                                                       NR
  Feng *et al*.\[[@ref30]\]      5 × 2 min × 4 min    NR                  Upper arm                    52                  Blank         180    NIHSS score; infraction volume; incidence of recurrent stroke; blood pressure                                                                                                                      NR
  Meng *et al*.\[[@ref29]\]      5 × 5 min × 5 min    200                 Upper arm                    90                  Placebo       180    Safety monitoring results: blood pressure and heart rate; local skin and muscle. Clinical outcome evaluation: Inflammation; coagulation and fibrinolysis; stroke and TIA recurrence; NIHSS score   Three cases with transient sporadic petechiae
  Zhang *et al*.\[[@ref27]\]     3 × 5 min × 5 min    200                 Upper arm                    60                  Blank         3      NIHSS score; hs-CRP; FIB, D-D                                                                                                                                                                      NR
  Jiang *et al*.\[[@ref28]\]     5 × 5 min × 5 min    200                 Upper arm                    90                  Placebo       180    Infraction volume; NIHSS score; blood pressure; hs-CRP ; Cystatin c                                                                                                                                NR
  Chen\[[@ref26]\]               5 × 5 min × 5 min    200--220            Upper arm                    90                  Placebo       14     NIHSS score; hs-CRP                                                                                                                                                                                NR
  Meng *et al*.\[[@ref24]\]      3 × 5 min × 5 min    200                 Upper arm                    60                  Blank         3      NIHSS score; serum glucose                                                                                                                                                                         NR
  Chen *et al*.\[[@ref23]\]      5 × 5 min × 5 min    200                 Upper arm                    90                  Placebo       180    Infraction volume; NIHSS score; blood pressure; incidence of cerebrovascular accidents                                                                                                             Two cases with limb mild pain, the symptoms disappeared completely after 30 min rest

1 mmHg = 0.133 kPa. I/R: Ischemic/reperfusion; mRS score: Modified Rankin Scale; Serum cAMP: Serum cyclic adenosine monophosphate; HIF-1: Hypoxic inducible factor-1; VEGF: Vascular endothelial growth factor; NIHSS: National Institute of Health Stroke Scale; BDNF: Brain-derived neurotrophic factor; BI: Barthel Index; FMA: Fugl-Meyer assessment; TIA: Transient cerebral ischemic attacks; hs-CRP: High-sensitivity C-reactive protein; FIB: Fibrinogen; D-D: D-Dimer; NR: Not report; RIPostC: Remote ischemic postconditioning.

###### 

Demographic characteristics of patients for included trials

  Study                          Age (years)    Male/female     Sample size (control versus study)   Population                    
  ------------------------------ -------------- --------------- ------------------------------------ ------------ ---------------- -----------------------------------------------------------------
  Ma *et al*.\[[@ref35]\]        52.90 ± 7.70   52.80 ± 12.70   5/3                                  3/5          8 versus 8       Intracranial arterial stenosis
  Meng *et al*.\[[@ref34]\]      60.00 ± 9.40   61.10 ± 10.10   19/11                                21/17        30 versus 38     Transient ischemic attack or cerebral infarction within 30 days
  Ru Juan *et al*.\[[@ref33]\]   54.0 ± 12.00   50.00 ± 13.00   41/19                                49/36        60 versus 85     Transient ischemic attack or cerebral infarction
  Wang *et al*.\[[@ref25]\]      NR             NR              4/5                                  5/4          9 versus 9       Acute cerebral infarction within 48 h
  Yang *et al*.\[[@ref32]\]      NR             NR              NR                                   NR           14 versus 32     Transient ischemic attack or cerebral infraction
  Peng *et al*.\[[@ref31]\]      NR             NR              NR                                   NR           20 versus 20     Acute cerebral infarction within 72 h
  Feng *et al*.\[[@ref30]\]      NR             NR              NR                                   NR           38 versus 44     Transient ischemic attack or cerebral infarction
  Meng *et al*.\[[@ref29]\]      84.20 ± 1.60   83.50 ± 2.30    17/11                                18/12        28 versus 30     Transient ischemic attack or cerebral infarction within 7 days
  Zhang *et al*.\[[@ref27]\]     54.89 ± 8.39   55.8 ± 8.63     69/67                                84/66        136 versus 150   Acute cerebral infarction within 72 h
  Jiang *et al*.\[[@ref28]\]     65.31 ± 7.36   64.82 ± 8.55    25/16                                22/19        41 versus 41     Acute cerebral infarction within 48 h
  Chen\[[@ref26]\]               61.78 ± 8.63   61.55 ± 8.53    22/14                                23/13        36 versus 36     Acute cerebral infarction within 3--24 h
  Meng *et al*.\[[@ref24]\]      NR             NR              NR                                   NR           69 versus 69     Acute cerebral infarction within 6--72 h
  Chen *et al*.\[[@ref23]\]      52.17 ± 8.62   53.96 ± 10.34   69/51                                43/37        80 versus 120    Transient ischemic attack or cerebral infarction

Data are presented as mean ± SD or *n*. NR: Not report; SD: Standard deviation.

Risk of bias assessment {#sec2-9}
-----------------------

Risk of bias in the included studies was independently assessed by two reviewers according to Cochrane Handbook 5.1. Reviewers' judgments about each risk of bias item presented as percentages across all included studies are presented in [Figure 2](#F2){ref-type="fig"}. Reviewers' judgments about each risk of bias item for each included study are presented in [Figure 3](#F3){ref-type="fig"}.

![Risk of bias graph: Review authors' judgments about each risk of bias item presented as percentages across all included studies.](CMJ-131-956-g002){#F2}

![Risk of bias assessment summary: Review authors' judgments about each risk of bias item for each included study. Green: Low risk of bias; Yellow: Unclear risk of bias; Red: High risk of bias.](CMJ-131-956-g003){#F3}

Allocation {#sec2-10}
----------

All included studies were described as randomized allocation. Four studies\[[@ref27][@ref28][@ref30][@ref35]\] used a random number table to allocate participants. All other studies claimed to be randomized, but did not describe how the randomization process was undertaken. This potentially created some selection bias. Concealment of allocation before enrollment was mentioned in only one study.\[[@ref29]\]

Blinding {#sec2-11}
--------

Two (15%) studies reported that the participants and investigators were blinded (low risk), while the remaining 11 (85%) studies were not masked to the RIPostC treatment of doctors and patients (high risk). Two (15%) studies were at low risk of detection bias (i.e., they reported that the outcome assessors were blinded), while the remaining 11 (85%) studies did not provide sufficient information for assessment (unclear risk). None of the trials used an appropriate blinding procedure.

Incomplete outcome data {#sec2-12}
-----------------------

All the included studies were judged to meet the criteria for low risk of incomplete outcome data (data are missing in two groups, and these were both reported and balanced across groups).

Selective reporting {#sec2-13}
-------------------

There is no enough information to judge whether it is high risk or low risk for all the included studies.

Other bias {#sec2-14}
----------

None of the trails reported the data management, statistical plan, or implementation process. All the included studies were judged by the investigators to meet the criteria for unclear.

Outcomes measurements {#sec2-15}
---------------------

**Incidence of stroke event**

Data regarding stroke event incidence were available in seven trials (615 participants: 357 participantsin the RIPostC group and 258 participantsin the control group) and were included in the meta-analysis. The incidence of stroke event was nominally lower in the RIPostC group than that in the control group (*RR* = 0.37; 95% *CI*: 0.26--0.55; *P* \< 0.00001; [Figure 4](#F4){ref-type="fig"}). There was low statistical heterogeneity among the included trials (heterogeneity, *χ*^2^ = 3.53; *I*^2^ = 0%; *P* = 0.62).

![Forest plot for incidence of cerebrovascular event. RIPostC: Remote ischemic postconditioning; *CI*: Confidence interval.](CMJ-131-956-g004){#F4}

**The National Institutes of Health Stroke Scale score**

Nine studies reported the NIHSS score. The meta-analysis revealed that RIPostC could significantly reduce the NIHSS score, when compared with the control group, through the random-effects model (MD: −2.60; 95% *CI*: −4.18--−1.02; *P* \< 0.001). The heterogeneity among the included trials was significant (heterogeneity, *χ*^2^ = 280.64; *I*^2^ = 97%; *P* \< 0.00001; [Figure 5](#F5){ref-type="fig"}).

![Forest plot for National Institutes of Health Stroke Scale score. RIPostC: Remote ischemic postconditioning; *CI*: Confidence interval.](CMJ-131-956-g005){#F5}

**The modified Rankin Scale score**

Merely two of the included studies reported the mRS score. The meta-analysis revealed that postconditioning could significantly reduce the mRS score, when compared with the control group (MD = −0.73; 95% *CI*: −1.19--−0.27; *P* = 0.002; heterogeneity, *χ*^2^ = 1.33; *I*^2^ = 25%; *P* = 0.25; [Figure 6](#F6){ref-type="fig"}).

![Forest plot for modified Rankin Scale score. RIPostC: Remote ischemic postconditioning; *CI*: Confidence interval.](CMJ-131-956-g006){#F6}

**High-sensitivity C-reactive protein**

Three studies reported hs-CRP. The meta-analysis revealed that postconditioning could significantly reduce hs-CRP, when compared with the control group (MD: −3.64; 95% *CI*: −4.71--−3.10; *P* \< 0.00001; heterogeneity, *χ*^2^ = 25.88; *I*^2^ = 0%; *P* = 0.88; [Figure 7](#F7){ref-type="fig"}).

![Forest plot for high-sensitivity C-reactive protein. RIPostC: Remote ischemic postconditioning; *CI*: Confidence interval.](CMJ-131-956-g007){#F7}

**Fibrinogen and D-Dimer levels**

Merely one study\[[@ref27]\] reported FIB and D-D levels as the outcome to evaluate the effect of RIPostC on stroke patients. The reported data revealed that RIPostC can reduce the levels of FIB (MD: −1.27; 95% *CI*: −1.49--−1.05; *P* \< 0.00001) and D-D (MD: −0.32; 95% *CI*: −0.38--−0.26; *P* \< 0.00001).

Additional analysis {#sec2-16}
-------------------

**Subgroup analysis**

The subgroup analysis based on treatment duration (≤14 days and \>14 days), RIPostC protocol (total duration/day \<90 min and ≥90 min), and stroke history (≤14 days and \>14 days) could not address the heterogeneity of the meta-analysis for the NIHSS score. The results are presented in [Table 3](#T4){ref-type="table"}.

###### 

Subgroup analysis of NIHSS score based on treatment duration, RIPostC protocol, and stroke history

  Subgroup                                 Number of study, *n*   Number of patients, *n*   Estimated effect (MD, 95% *CI*)   *I*^2^ (%)   Analysis model   *Z*    *P*
  ---------------------------------------- ---------------------- ------------------------- --------------------------------- ------------ ---------------- ------ -------
  Treatment duration (days)                                                                                                                                        
   ≤14                                     5                      626                       2.38 (−4.52, −0.24)               98           Random           2.18   0.030
   \>14                                    4                      350                       2.88 (−5.11, −0.65)               92           Random           2.54   0.010
  RIPostC protocol (total duration, min)                                                                                                                           
   \<90                                    5                      508                       2.26 (−4.45, −0.07)               98           Random           2.02   0.040
   ≥90                                     4                      468                       3.01 (−5.09, −0.94)               92           Random           2.85   0.004
  Stroke history (days)                                                                                                                                            
   ≥14                                     7                      756                       2.25 (−3.91, −0.59)               97           Random           2.66   0.008
   \>14                                    2                      220                       3.77 (−7.41, −0.13)               91           Random           2.03   0.040

NIHSS: National Institute of Health stroke scale; RIPostC: Remote ischemic postconditioning; MD: Mean difference; *CI*: Confidence interval.

**Sensitivity analysis**

To assess for the robustness of the present findings, a sensitivity analysis was performed. A random-effects model was used when statistical heterogeneity was high, which did not alter the results (data not shown). The sensitivity analysis, which deleted each trial one at a time, revealed that no single study significantly altered the summary MD for the NIHSS score. Merely two studies had low risk of bias relating to allocation concealment and the blinding of participants. At the end of the treatment, the NIHSS score was lower in patients who received placebo than those who received blank.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Summary of evidences {#sec2-17}
--------------------

In the present study, the included RCTs were reviewed to evaluate the effect of RIPostC, which is a noninvasive and nonpharmacological method for stroke. With statistical significance, RIPostC decreased the risk of cerebrovascular event in patients undergoing ischemic stroke, when compared with controls. In the present meta-analysis, a total of 13 trials were included, which enrolled 794 patients. To our knowledge, this is the first meta-analysis that focused on the effect of RIPostC on ischemic stroke. These results revealed that RIPostC was better, compared with placebo or no add-on treatment, in the incidence of stroke events and NIHSS scores. In the secondary outcome measurement, including the mRS scores and plasma levels of hs-CRP, patients in the RIPostC group were better than the controls. In terms of safety, there was a report of three patients in the process of RIPostC treatment\[[@ref29]\] and patients with locally scattered ecchymosis. However, these symptoms disappeared after stopping RIPostC. Another study\[[@ref23]\] revealed that two patients with limb compression training appeared to have mild pain, and these symptoms completely disappeared after a 30-min rest. All studies reported no death, regardless of whether it was from the RIPostC group or control group.

The protective effect of RIPostC on patients with IRI is more complex, but remains unclear, and this might be related to the patient\'s body in terms of anti-oxidation, anti-infection, the regulation of protein expression, and so on. In recent years, a study reported\[[@ref36]\] that hs-CRP was potentially related to the occurrence and development of atherosclerosis and was considered to be one of the factors of cerebral infarction. The FIB level reflects the decline of the body\'s fibrinolytic activity and is regarded as one of the risk factors of cerebral infarction.\[[@ref37]\] D-D can be used as a sensitive indicator for the early diagnosis of cerebral infarction.\[[@ref38]\] This study revealed that RIPostC reduced hs-CRP levels. A study also reported that RIPostC can reduce the levels of FIB and D-D.\[[@ref27]\] Therefore, it can be speculated that RIPostC has a certain role in promoting the recovery of neurological function in patients with ischemic stroke.

At present, there are few studies on the intensity of RIPostC implementation. Loukogeorgakis *et al*.\[[@ref39]\] carried out a study (5-min ischemia/5-min reperfusion, two cycles) on the protection of the skeletal muscle of the upper limb and obtained the conclusion that it has an obvious protective effect. In addition, Li *et al*.\[[@ref40]\] also reported that the intensity of the skeletal muscle after 5-min ischemia/1-min reperfusion can have a significant protective effect on the myocardium. However, there are few studies on RIPostC of different intensities, and there is no report on whether this mode intensity is the best and the other treatment intensity is different. In addition, there are also no reports on the effects of the time window of the limb ischemia and intensity of treatment on the degree of ischemia. Hence, it is necessary to conduct a study to find a better solution for the treatment of RIPostC. The results reported by Loukogeorgakis *et al*.\[[@ref39]\] indicated that there may be a minimum threshold value for the protective effect of RIPostC. At the right time, 5 min of treatment intensity can have a significant role in myocardial protection, when the implementation of strength is ≤3 min, losing significant protective effect on the heart. However, in a 5-min basis, an increase in processing intensity does not increase the protective effect.\[[@ref41]\]

The optimal conditioning protocol (cycles × I/R) for RIPostC to elicit organ protection in humans remains unknown. One laboratory study conducted by Xin *et al*.\[[@ref42]\] revealed that 3--4, and not 1--2 cycles of 5-min/5-min RIPostC, could provide additive cardioprotection to local postconditioning, and similar results were obtained in four cycles of 3-min/3-min or 1-min/1-min. Prasad *et al*.\[[@ref41]\] did not find any protective effect for three cycles of 3-min RIPostC on the cardiac enzyme levels of cardiac troponin T or MB isoenzyme of creatine kinase (CK-MB), percutaneous coronary intervention (PCI)-related myonecrosis rate, or myocardial infarction (MI) occurrence. Two cycles of 5-min RIPostC were also proven to reduce cardiac enzyme levels and the PCI-related myonecrosis rate in the study conducted by Ghaemian *et al*.\[[@ref43]\] Moreover, one cycle of 5-min RIPostC remained to be cardioprotective in Zografos *et al*.\'s study.\[[@ref44]\] In summary, the present evidence suggests that 5-min ischemic stimulus for conditioning protocol in RIPostC is essential. In this review, eight of 13 of the included studies used five cycles of 5-min/5-min, three studies used three cycles of 5-min/5-min, one study used three cycles of 5-min/10-min, and one study used five cycles of 2-min/4-min for conditioning. This might influence the results of RIPostC on patients with stroke. Due to the quantity of included studies, a subgroup analysis could not be conducted. Future studies should verify whether the increase in conditioning cycle of RIPostC might result in enhanced organ protection in these clinical settings. Therefore, it is possible that some studies used a form of conditioning, which is not sufficient to achieve the maximal protective effect.

This review revealed that the adjunct use of RIPostC resulted in a larger reduction in NIHSS scores. This result suggests that the estimated effect of RIPostC as a cointervention to conventional treatment is relevant and potentially important to stroke patients in real-world practice.

Limitations {#sec2-18}
-----------

Although the meta-analysis provided information on the role of RIPostC in ischemic stroke patients, several limitations should be considered. First, most of the methodological quality of the included studies is not high. The present study revealed that remote postconditioning reduced the incidence of stroke or TIA. Second, in the parameters for conditioning, the procedure of postconditioning was not unified in the included studies. Finally, in the present review, RCTs of various interventions were included to gain a broad perspective on evidences regarding the use of RIPostC for ischemic stroke, and this caused heterogeneity in the meta-analysis. In addition, clinical and methodological heterogeneity could not be well addressed by subgroup or sensitivity analysis. Therefore, most results presented in this review were the average effects of RIPostC on stroke estimated by a random-effects model.

CONCLUSION {#sec1-5}
==========

In summary, this study reveals that RIPostC decreases the risk of cerebrovascular event in patients undergoing ischemic stroke, when compared with controls. However, the included studies are of low methodological quality and had a limited scope, and the results have some inevitable biases. Future research should clarify the mechanism, in order to explore the full play of its cerebral protective effect. At the same time, it is necessary to have a high-quality, large scale, multi-center RCT for RIPostC.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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